Who’s “we”?

This article is making the rounds and getting some attention. The post below addresses the issues raised. (originally posted on 10/31/2014) ==================================== This article has been forwarded to me by several people. Its author has been writing a series of articles that seek to redefine addiction and recovery. As Eve Tushnet recently observed, "There’s another narrative, … Continue reading Who’s “we”?

Who’s “we”?

This article has been forwarded to me by several people. Its author has been writing a series of articles that seek to redefine addiction and recovery. As Eve Tushnet recently observed, "There’s another narrative, though, which is emerging at sites like The Fix and Substance.com." This sentence is representative of this alternative narative: "The addiction field has struggled … Continue reading Who’s “we”?

ASAM president also medical director for drug company

I missed this a while back. Turns out that ASAM's president works for a buprenorphine manufacturer. Stuart Gitlow, M.D., is the president of the American Society of Addiction Medicine (ASAM) and also medical director — as a consultant — for Orexo, which makes Zubsolv, a newly approved buprenorphine-naloxone medication (see ADAW, July 15). The first public … Continue reading ASAM president also medical director for drug company

NAATP launches counteroffensive to medication push

This is very welcome news: Frustrated that medication-assisted treatment is coming across as the addiction field’s standard of care simply because drug company studies are dominating the research landscape, a group of some of the most prominent leaders in treatment administration is vowing to fight back. These leaders have enlisted the help of another heavy … Continue reading NAATP launches counteroffensive to medication push